Cytyc Corporation Appoints New Independent Auditor.

Business/Technology Editors & Health/Medical Writers

BOXBOROUGH, Mass.--(BW HealthWire)--May 21, 2002

Cytyc Corporation (Nasdaq:CYTC) announced today that its Board of Directors has appointed Deloitte & Touche LLP as the Company's independent auditor, replacing Arthur Andersen LLP. The change is effective today.

The appointment of Deloitte & Touche was made by the Board of Directors on the recommendation of its Audit Committee, which conducted a thorough assessment of the Company's needs for independent audit services, to ensure that shareholders will continue to maintain confidence in the integrity of the Company's financial statements. The decision to change auditors was not the result of any disagreement between Cytyc Corporation and Arthur Andersen on any matter of accounting principles, practices, or financial disclosure.

"The Boston-based Arthur Andersen team has provided quality audit services to Cytyc since 1987 and the Company thanks the engagement team for its dedicated and professional work," said Patrick J. Sullivan, Cytyc's vice-chairman, chairman-elect, and chief executive officer.

Cytyc Corporation develops, manufactures and markets products for medical diagnostic applications primarily focused on women's health. Cytyc's ThinPrep(R) System is widely used for cervical cancer screening and serves as a platform for the Company's expansion into breast cancer risk assessment with the FirstCyte(TM) Ductal Lavage device. The ThinPrep System consists of the ThinPrep(R) 2000 Processor, ThinPrep(R) 3000 Processor, and related reagents, filters, and other supplies. Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC and is a part of the S&P Midcap 400 Index and The Nasdaq-100 Index.

Cytyc(R) and ThinPrep(R) are registered trademarks of Cytyc Corporation. FirstCyte(TM) is a trademark of Cytyc Corporation for which registration has been applied.